Biologics and Clinical Immunology Patient Registry at Mount Sinai for Immunological and Autoimmune Diseases

What this Trial Is About

Researchers are establishing a bioregistry to study patients receiving biologic therapy as part of their standard treatment for immunological diseases, autoimmune diseases, and primary immune deficiency. This observational study aims to collect detailed demographic, immunologic, exposure, and clinical data to better understand how patients respond to biologic treatments. The research also focuses on developing novel diagnostics to improve the effectiveness of these therapies and addresses key questions about how different biologic treatments impact immune responses and clinical outcomes. The study involves creating a flexible biorepository and database that incorporates biological specimens and questionnaire data. Most participants will be recruited from the Mount Sinai Therapeutic Infusion Center, with additional participants receiving infusions elsewhere or at home included from affiliated outpatient practices. The registry is designed to support ongoing and future research questions, including the effects of specific biologics such as anti-IgE, anti-IL-5, anti-TNF, anti-CD20, and IVIG therapies on immunological pathways and clinical outcomes. Participants will be involved in data and specimen collection over a period of up to three years. The study will use various health questionnaires like the Asthma Control Questionnaire and Clinical Disease Activity Index to track clinical status. Researchers will monitor immunological markers and disease activity scores to assess treatment responses. This long-term observation aims to support precision medicine approaches by linking immunophenotype data with clinical outcomes and facilitating multidisciplinary research collaborations.

Biologics And Clinical Immunology Cohort at Sinai